Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 159,588 261,929 319,053 656,089
Total Sell Value $13,270,852 $22,448,451 $27,661,182 $61,420,002
Total People Sold 5 6 7 7
Total Sell Transactions 10 20 27 56
End Date 2024-03-17 2023-12-15 2023-06-16 2022-06-16

   
Records found: 1303
  Page 45 of 53  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Kakkis Emil D Chief Medical Officer   •       –      –    2008-03-06 4 OE $4.00 $72,000 D/D 18,000 104,164     -
   Grey Michael G Director   –       •      –    2008-03-05 4 S $38.39 $134,446 D/D (3,500) 5,000     -
   Grey Michael G Director   –       •      –    2008-03-05 4 S $38.03 $820,682 D/D (21,500) 8,500     -
   Grey Michael G Director   –       •      –    2008-03-05 4 OE $10.33 $309,900 D/D 30,000 30,000     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2008-03-04 4 S $38.00 $152,000 D/D (4,000) 7,213     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2008-03-04 4 OE $6.46 $25,840 D/D 4,000 31,213     -
   Klein Joseph III Director   –       •      –    2008-03-03 4 S $38.00 $380,333 D/D (10,000) 30,000     -
   Klein Joseph III Director   –       •      –    2008-03-03 4/A S $37.80 $758,333 D/D (20,000) 20,000     -
   Heron Elaine J Director   –       •      –    2008-03-03 4 S $38.47 $769,400 D/D (20,000) 0     -
   Davis George Eric VP, General Counsel   •       –      –    2008-03-03 4 S $38.00 $760,000 D/D (20,000) 3,397     -
   Davis George Eric VP, General Counsel   •       –      –    2008-03-03 4 OE $6.13 $149,960 D/D 20,000 23,397     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2008-03-03 4 S $38.10 $76,239 D/D (2,000) 11,213     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2008-03-03 4 OE $6.46 $12,920 D/D 2,000 27,213     -
   Aselage Steve SVP, Global Commercial Dev   •       –      –    2008-03-03 4 S $38.00 $1,520,000 D/D (40,000) 32,034     -
   Aselage Steve SVP, Global Commercial Dev   •       –      –    2008-03-03 4 OE $7.16 $593,640 D/D 65,000 72,034     -
   Klein Joseph III Director   –       •      –    2008-02-29 4 OE $14.21 $426,300 D/D 30,000 40,000     -
   Cooper Jeffrey H SVP, Chief Financial Officer   •       –      –    2008-02-29 4 S $37.82 $224,058 D/D (5,905) 1,005     -
   Lapalme Pierre Director   –       •      –    2008-02-29 4 S $37.53 $341,101 D/D (9,025) 12,575     -
   Lapalme Pierre Director   –       •      –    2008-02-29 4 OE $5.92 $88,800 D/D 15,000 21,600     -
   Klein Joseph III Director   –       •      –    2008-02-29 4/A OE $14.21 $426,300 D/D 30,000 40,000     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2008-02-29 4 S $37.91 $805,798 D/D (21,142) 4,071     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2008-02-29 4 OE $6.46 $116,280 D/D 18,000 25,213     -
   Lapalme Pierre Director   –       •      –    2008-02-29 4 S $38.06 $229,615 D/D (5,975) 6,600     -
   Cooper Jeffrey H SVP, Chief Financial Officer   •       –      –    2008-02-29 4 S $37.53 $1,870,362 D/D (49,720) 6,910     -
   Cooper Jeffrey H SVP, Chief Financial Officer   •       –      –    2008-02-29 4 OE $5.15 $520,873 D/D 55,625 56,630     -
  1303 Records found
  Previous  40  41  42  43  44  45  46  47  48  49  Next   
  Page 45 of 53
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us